Zacks Investment Research on MSN

How strong is AbbVie's immunology franchise after Humira's LOE?

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — ...
NBC DFW

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...
FiercePharma

AbbVie jacks up 2027 sales projection for star duo of Skyrizi, Rinvoq to $31B

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday, when AbbVie ...
Morningstar

AbbVie Earnings: Solid Drug Sales Help Mitigate Humira Biosimilar, but Increased Pressure Expected

AbbVie posted first-quarter results largely as projected, and we don’t expect any major changes to our fair value estimate. With the arrival of the first U.S. biosimilar to Humira, AbbVie’s results ...
Seeking Alpha

Despite Humira's Challenges, AbbVie's Execution Makes It A Buy

AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth. The company has a solid track record of increasing dividends and offers an attractive current ...
Nasdaq

AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals

Feb 2 (Reuters) - AbbVie Inc ABBV.Nbeat Wall Street estimates for fourth-quarter profit on Friday, helped by a smaller-than-expected decline in sales of its blockbuster drug, Humira, and strong demand ...
Reuters

Abbott sales jump, but Humira sales weigh on stock

NEW YORK, Jan 27 (Reuters) - Abbott Laboratories reported stronger-than-expected fourth-quarter results, helped by lower taxes and reduced expenses, but weak U.S. sales of its Humira arthritis drug ...